The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Imm has strong fundamental and great potential, ofcourse this comes with risk as lot of uncertainty! But considering Avion with them on Lupuzor which itself can be worth £2-£5 per share , then it has Ureka for covid and few others, also fully funded for next 12 months . just need a few good rns , positive update on SPA etc . Sp will move up soon
DYoR
That’s why it’s important to diversify portfolio... so if one down other will rise! I’m holding a couple of pharma stocks, i mentioned last time about OrPh, so far I’m up 40%. Initially I was down too but it started going up after a few good rns! Today another OMi ( gold mining) up 100% was sitting on paper loss by 70%, it dropped to 2p now 10p!
It’s game of patience, once you have done your research, sit tight and don’t look at daily movements! If you believe in co fundamental daily ups and down shouldn’t affect ! Just my view ... DYoR
I don't know anything about VAL Bojo and I'm not saying it's a bad company. I was just talking in general terms. A lot of people have probably got burnt so will be more cautious on other investments. That's not necessarily a bad thing as too much speculation is not good for any of us as it can spread and cause problems for other investors.
I still remain positive here let's hope we get good news.
VAL delivered flat results on its latest clinical trial for VAL201. It proved itself to be safe but ineffective. That is a crying shame as it wasted everybody's time and money. It may yet prove to be safe and effective but only time will tell. I would guess that as many as half the retail investors just don't understand the science or the consequences of that result. Maybe they will do better with VAL401?? No matter what, remaining invested in that stock becomes so much more of a bigger gamble. Not dissimilar to our holding here. If we get the result we though we might, then IMM will have turned a new page and we all start afresh. I really hope that is the case as the world needs drugs like Lupizor.
Yes strange days. Maybe it's the Val effect?
I always aim to be in quality businesses in case there is a downturn and then you're stuck with them. The quality businesses are more likely to pull through/survive over the long term.
During the dot com craze of the late 90's all sorts of rubbish increased as well as the good businesses and then investors were left holding them many of which went bust later.
I'm not sure if biotech valuations are over stretched here - I would say not but over the pond they probably are? They have always been high there though you have biotech companies valued in the billions there that would be worth maybe 200-300 million here. Strange that.
With Imm the management leaves a lot to be desired but I'm holding it on "value" principles and hoping the science pulls us through in spite of the management.
Well SNG have a long and difficult journey but I think the BOD are doing the best possible considering. Cant see a big pharma stepping in unless SNG cross many of the hurdles on its own first.
DNL got FDA approval but they didn't gain. Just goes to show that investing takes patience lol.
SCLP held firm but the AGM may change that in a few weeks for better or worse.
Imm, well let us pray!
I didn't expect that with sng to be honest. It have a tiny holding free carried but I'm thinking I should have sold around 220 when I had the chance.
Think Scoredagainsteps is one of the few people who have made money on imm so far.
Biotechs have had a good run so far - everything has been lifted pretty much (except us).
It is a day we’ll want over
I think a few people here my also be into sng
Horror show
noticed more buyers here book firming up ?
1509 i was joking i know she likes a drink .. MY OTHER PHARMA FDA APPROVED AND FINISHED RED
Too late.
I think Eva had already turned to drink before
LETS HOPE eva dont turn to the drink because her shares have tanked
Cheers nolupus on my other pharma
Leas,
We never agreed on anything except the good French wine :-)
Anyway , let's see where we go from here ...
No lupus
We had many disagreements post P3 trial. However, when I read the trial design I decided on my strategy to sell prior to the the results. I think the debate was in how affective it was.
Secondly, I did not agree on the number of patients in Mauritius due to their healthcare and possibility of skewed results.
For what it’s worth, if I had lupus then a small reduction in my pain suffering or symptoms is better than nothing. Lupuzor would be my choice rather than the damaging alternatives.
Leas,
You did'nt agree with me at the time when I said that the trial criteria was flawed ...we had quite a few run arguments about that if my memory is correct ...
Anyway here we are awaiting the FDA verdict on our new protocol and Avion must have used the pressure building on the FDA to change their endpoints on Lupus trials . The KOLs and Lupus organisations are awaiting the changes to finally bring some hope to Lupus sufferers ... Will the FDA let IMM be the first out the door or not ? The delay in the SPA response is more down to this than COvid delays, imv ( they are trying to find a consensus, within the FDA is my bet )
Only time will tell ....
Likewise score but to be honest I got lucky, only strategy was take the risk of selling prior to P3 taking advantage of the rise leading up to them. That said, I did think the last trials would be a success given the Fast Track status. (If the benefits outweigh the risks) and from previous trials there was not much evidence if any to say Lupuzor was unsafe. I do think the last trial design was wrong with too much ask on the SLEDAI scale in order for it to be deemed a benefit.
Wish you and your fellow investors the very best here and with your other investments.
LEAS i agree with you .. A lot of people sell for different reasons . IF like you invest for ten years you can hit the jackpot like you did . IM VERY GRATEFULL to imm it has looked after me .Atb leas
Having read today's RNS then I wouldn't say the financials are robust. Admin expenses up, R&D down. In fact more being spent on the latter. Partnerships are pivotal in IMM's success and if Lupuzor does succeed at the P3 stage then I can see a handsome offer to shareholders for the entire rights. Timing is everything lets hope the trial is completed before 2023.
Maybe a few private investors selling today but no drama.
Just had a email back from lisa always a swift reply .No worries imo she says every case is different and they want the best for everyone . On that i feel a lot better might even add
1509, could you post the reply from FDA here?
Andle
I googled the link that was in you post but nothing came back.
I have been in touch with the FDA asking if the guidance has changed because of its increased workload as a result of covid and I received a response saying that it has not affected the time they take to deal with submissions
1509. I do like a theory but you will have to do better than that......
accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process.
1509 great news dnl i did wonder that but eton has a history with the fda so maybe that helps .ANY way im holding as i know how quick imm can turn atb
So DNL get its FDA approval in connection with an application with no specific time period for the FDA to consider it. I understand that they try and turn applications around within 6 to 10 months.
We have a specific time period ie within 45 calendar days. No news apart from the RNS saying there is a delay.
Avion's submission must be straight forward to consider compared to other matters the FDA are dealing with.
I don't really buy the information contained in the RNS.
I think something is going on behind the scenes. Avion as a private company so do not need to release information. IMM do however within a reasonable time of receiving it.
I think Avion has heard back from the FDA and IMM are aware of this.
Possibly for some strategic reason IMM are holding onto information. Possibly to combine the release of information on Lupuzor with something else going on in the company.
Any thoughts?